Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
HIV/AIDS
Genetic Immunity Announces Data Related to the DermaVir Nanomedicine Patch in the Journal of Immunology
May 7th, 2008
Genetic Immunity(R), a US/Hungarian clinical-stage company focused on patented nanomedicines for immune amplification, announced that the Journal of Immunology published findings on a key biomarker currently being used in clinical studies of its lead HIV/AIDS nanomedicine candidate, the DermaVir Patch. The paper, entitled "HIV-1-Specific T-Cell Correlate with Low Viremia and High CD4 Counts in Untreated Individuals," highlights data from a study conducted by Sandra Calarota, Ph.D., of the Research Institute for Genetic and Human Therapy (RIGHT). In Dr. Calarota's study of 32 HIV-1 infected individuals, high immunological responses measured by a novel assay of T cell...
Source: Vaccine Weekly (2008-05-07)
|
